Evidence map›Paper›PMID 26848272›Full record

ReviewInfection and drug resistance2016

A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections.

Aditya K Gupta, Deanne Daigle

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infection and drug resistance, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Tinea pedis: an updated review.Drugs in context · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Tinea corporis: an updated review.Drugs in context · 2020
    Review
  11. A 23 bpFrontiers in microbiology · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Aditya K GuptaDepartment of Medicine, University of Toronto School of Medicine, Toronto, Canada; Dermatology, Mediprobe Research Inc., London, ON, Canada.
Deanne DaigleDermatology, Mediprobe Research Inc., London, ON, Canada.
Mediprobe Research (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Luliconazole is a novel imidazole derivative, which has demonstrated in vitro efficacy against dermatophytes and Candida. The results from Phase III trials show that luliconazole 1% cream applied once daily for 2 weeks successfully resolved the clinical signs and symptoms as well as eradicated the pathologic fungi, which cause tinea pedis. A 1-week treatment with luliconazole 1% cream also produced favorable clinical and mycological results in clinical trials for tinea corporis and tinea cruris. Across trials, adverse events consisted mainly of localized reactions following application. The development of a new antifungal agent is timely due to mounting resistance among existing treatments. Because luliconazole requires a short duration of treatment, it may assist in reducing disease recurrence as a result of patient nonadherence.

Indexed as

antifungalathlete’s footdermatophyteimidazoletinea corporistinea cruris

Identifiers

PMID26848272
PMCPMC4723097
OpenAlexW2269862489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.